<DOC>
	<DOCNO>NCT00369837</DOCNO>
	<brief_summary>The purpose study determine safety clevidipine treat severely elevate blood pressure , define systolic ( SBP ) &gt; 180 mmHg and/or diastolic blood pressure ( DBP ) &gt; 115 mmHg assess 2 successive occasion 15 minute apart baseline , patient without major organ injury , particularly respect control dose adjustment desire effect prolong continuous infusion . Enrollment patient study continue target goal 100 patient least 18 hour continuous clevidipine treatment , include minimum 50 patient acute chronic end-organ injury , meet .</brief_summary>
	<brief_title>Clevidipine Treatment Patients With Severe Hypertension ( VELOCITY )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Clevidipine</mesh_term>
	<criteria>Age 18 year old Systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 115 mmHg assess two successive occasion , 15 minute apart baseline Written inform consent SBP ≤180 mmHg and/or DBP ≤115 mmHg Expectation patient tolerate intravenous antihypertensive therapy least 18 hour Known suspected aortic dissection Administration agent treat hypertension within 2 hour clevidipine administration Severe hypertension know precipitate use , withdrawal , alcohol illicit drug , intentional overdose illicit prescription drug Positive pregnancy test Intolerance calcium channel blocker Allergy soybean oil egg lecithin Known liver failure cirrhosis Participation clinical research study investigational drug device within 30 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>